Among the most beneath-investigated “driving forces” involved with trastuzumab resistance is PTEN. Nagata et al. (2004) claimed that the lack of PTEN was noticed in 36% of HER2-optimistic primary breast tumor specimens from clients with stage IV sickness. Also, In addition they showed th